SCYX / Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)

We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturin more_horizontal

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme. more_horizontal

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global res more_horizontal

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0. more_horizontal

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also contin more_horizontal

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS more_horizontal

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an more_horizontal

SCYNEXIS, Inc. (NASDAQ:SCYX ) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications & IR D more_horizontal